Regression of CD30+ cutaneous anaplastic large-cell lymphoma with denileukin diftitox

Journal of the American Academy of Dermatology

Volumn 64, Issue 6, 2011, Pages

  Dao Jr , Harry ^a   Barr, Paul M ^a   Honda, Kord ^a  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD30 ANTIGEN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DENILEUKIN DIFTITOX; DEXAMETHASONE; METHOTREXATE; PREDNISOLONE; VINCRISTINE; VORINOSTAT;

ADULT; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DRUG DOSE ESCALATION; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN TISSUE; LARGE CELL LYMPHOMA; LETTER; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PUNCH BIOPSY; SKIN BIOPSY;

EID: 79956066251     PISSN: 01909622     EISSN: 10976787     Source Type: Journal    
DOI: 10.1016/j.jaad.2010.11.001     Document Type: Article

References (2)

1. Olsen E, Duvic M, Frankel A, Kim Y, Martin A, Vonderheid E, et al. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J Clin Oncol 2001;19:376-88. (Pubitemid 32112849)
2. Foss FM, Bacha P, Osann KE, Demierre MF, Bell T, Kuzel T. Biological correlates of acute hypersensitivity events with DAB(389)IL-2 (denileukin diftitox, ONTAK) in cutaneous T-cell lymphoma: decreased frequency and severity with steroid premedication. Clin Lymphoma 2001;1:298-302.